Rheumatoid Arthritis Completed Phase 4 Trials for Certolizumab pegol (DB08904)

Also known as: RA / Rheumatic Arthritis / Arthritis, Rheumatoid / Arthritis,Rheumatoid / Rheumatoid Arthritis (RA) / Rheumatoid Arthritis(RA) / Arthritis, Rheumatoid (RA) / Systemic rheumatoid arthritis / Arthritis rheumatoid / Rheumatoid arthritis, unspecified / R arthritis / Rh arthritis / Atrophic arthritis

IndicationStatusPhase
DBCOND0027961 (Rheumatoid Arthritis)Completed4
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02451748IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIABasic Science
NCT00580840Dosing Flexibility Study in Patients With Rheumatoid ArthritisTreatment
NCT00993668Assessing the Use of Certolizumab Pegol in Adult Subjects With Rheumatoid Arthritis on the Antibody Response When Receiving Influenza Virus and Pneumococcal VaccinesTreatment
NCT01255761A Comparison of Two Assessment Tools in Predicting Treatment Success of Cimzia in Rheumatoid Arthritis SubjectsTreatment
NCT01500278Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to MethotrexateTreatment
NCT01443364Open Label Study to Assess the Predictability of Early Response to Certolizumab Pegol in Patients With Rheumatoid ArthritisTreatment
NCT01295151SWITCH Clinical Trial for Patients With Rheumatoid Arthritis Who Have Failed an Initial TNF-blocking Drug.Treatment
NCT01147341Can TNF-Alpha Incomplete Secondary Responders Attain a Safe and Efficacious Response Switching to CimziaTreatment
NCT01098201Certolizumab and Lower Extremity Lymph Flow in Rheumatoid Arthritis (RA)